BCAL Diagnostics Limited ABN 51 142 051 223 Suite 506 Level 5 50 Clarence Street Sydney NSW 2000 15 October 2026 ASX Announcements BCAL Diagnostics Limited – Letter to Genetic Signatures Limited Shareholders As the largest shareholder in Genetic Signatures Limited (GSS), BCAL Diagnostics...
Letter to Genetic Signatures Ltd Shareholders
Filed with ASX · · 7 pages · English
Release
BCAL Diagnostics Limited on 6ix
Story so far
Earlier from BCAL Diagnostics
- Investor Presentation - Transforming Cancer Detection
- Change in substantial holding
- BREASTESTplus 2 clinically validated
- BCAL Introduces Avantect Multi-Cancer Early Detection Test
- Letter to Shareholders re Annual General Meeting
Later from BCAL Diagnostics
- GSS: Response to Media Speculation & BCAL letter to GSS
- BREASTESTplus Research Presented at Lipidomic Conference
- AGM 2026 Presentation
- Results of Meeting
- BCAL Welcomes Dr John Melki's Appointment to GSS Board
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics